Proper assessment of risk factors contributes to the principle management of differentiated thyroid carcinoma post operatively. Aim of the study: to investigate the effect of Thyroglobulin (Tg) levels on prognosis together with other risk factors for Differentiated Thyroid Cancer (DTC). Patients and methods: Medical records of all patients with DTC presented to Clinical Oncology and Nuclear Medicine Department referred from Diabetes & Endocrine unit (Internal Medicine Hospital) and Surgery Department Mansoura University from 2011-2016 were retrospectively reviewed. Patients with distant metastasis or who lost follow-up were excluded. So data of 220 patients were analyzed. Data collected included pre-surgical assessment, also surgical interference either total or near total thyroidectomy with or without lymph node neck dissection were reviewed. Different prognostic factors that affect progression free survival (PFS) include age, umorsize, ymph node status, ex, m ultifocality, capsular infiltration, vascular invasion and Tg level were evaluated through multivariate analysis. Results: Most of the patients included were <45 years (69.1%). Incidence of the disease was higher in female ( 80%) with papillary type predominance (80.9%). About 59.5% of cases presented with tumor size ≤ 2 cm and multifocality was reported in 13.6%. While 30% had lymph node metastasis, 11% had vascular invasion. Capsular infiltration was observed in 15% and most of them showed Tg level ≤ 10 ng/ml (68.2%). About 70% received ablative radioiodine. The 5-year Progression Free Survival (PFS) was 85%. On multivariate analysis of variable prognostic factors on PFS , we found that tumor size, age, lymph node status, capsular infiltration, Tg level and vascular invasion significantly affect ed PFS (P = 0.01, 0.005, 0.004, 0.005, 0.02, 0.003) respectively. While sex, pathological type and multifocality were not (P = 0.9, 0.4, 0.6) respectively. Conclusion: Postoperative Tg level is a statistically significant prognostic factor together with other risk factors .
Eustatia-Rutten, C.F., Corssmit, E.P., Biermasz, N.R., et al. (2006) Survival and Death Causes in Differentiated Thyroid Carcinoma. The Journal of Clinical Endocrinology & Metabolism, 91, 313-319. https://doi.org/10.1210/jc.2005-1322
Hundahl, S.A., Fleming, I.D., Fremgen, A.M., et al. (1985) A National Cancer Data Base Report on 53,856 Cases of Thyroid Carcinoma Treated in the U. S. Cancer, 83, 2638-2648. https://doi.org/10.1002/(SICI)1097-0142(19981215)83:12 3.0.CO;2-1
Torlontano, M., Crocetti, U., Augello, G., et al. (2006) Comparative Evaluation of Recombitant Human Thyrotrobin-Stimulated Thyroglobulin Levels, 131I Whole-Body Scintigraphy and Neck Ultrasound in the Follow-Up of Patients with Papillary Thyroid Microcarcinoma Who Have Not Undergone Radioiodine Therapy. The Journal of Clinical Endocrinology & Metabolism, 91, 60-63. https://doi.org/10.1210/jc.2005-1185
Makarewicz, J. and Lewin’ski, A. (2004) Prognostic Factors in Patients with Differentiated Thyroid Carcinoma. PostepyHig Med Dosw (Online), 58, 514-521.
Mazzaferri, E.L. and Kloos, R.T. (2001) Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism, 86, 1447-1463. https://doi.org/10.1210/jcem.86.4.7407
Leung, A.M., Dave, S., Lee, S., et al. (2011) Factors Determining the Persistence or Recurrence of Well-Differentiated Thyroid Cancer Treated by Thyroidectomy and/or Radioiodine in the Boston, Massachusettsarea: A Retrospective Chart Review. Thyroid Research, 4, 9. https://doi.org/10.1186/1756-6614-4-9
Juszczyk, K.G. and Kowalska, A. (2015) Comparison of the Usefulness of Post-Ablative and Post-Operative Thyroglobulin Concentration Measuring in Prognostic Assessment of Patients with Differentiated Thyroid Cancer. Endokrynologia Polska, 66, 486-494.
Baloch, Z., Carayon, P., Conto-Devolex, B., et al. (2013) Laboratory Medicine Practice Guidelines. Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease. Thyroid, 13, 3-126.
Sawaka, A.M., Orlov, S., Gelberg, J., et al. (2008) Prognostic Value of Postsurgical Stimulated Thyroglobulin Levels after Initial Radioactive Iodine Therapy in Well-Differentiated Thyroid Carcinoma. Head Neck, 30, 693-700. https://doi.org/10.1002/hed.20755
Heemstra, K.A., Liu, Y.Y., (2007) Stokkel Metal. Serum Thyroglobulin Concentration Predict Disease-Free Remission and Death in Differentiated Thyroid Carcinoma. ClinEndocrinol (Oxf), 66, 58-64.
Toubeau, M., Touzery, C., Arveux, P., et al. (2004) Predictive Value for Disease Progression of Serum Thyroglobulin Levels Measured in the Postoperative Period and after 131I Ablation Therapy in Patients with Differentiated Thyroid Cancer. Journal of Nuclear Medicine, 45, 988-994.
Stephen, B. and Carolyn, C. (2010) The American Joint Committee on Cancer: The 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Annuals Surgical Oncology, 17, 1471-1474.
Haugen, B.R., Alexander, E.K., Bible, K.C., et al. (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26, 1-133. https://doi.org/10.1089/thy.2015.0020
Ruegemer, J., Hay, I., Bergstraih, E., et al. (1988) Distant Metastasis in Differentiated Thyroid Carcinoma: A Multivariate Analysis of Prognostic Variables. The Journal of Clinical Endocrinology & Metabolism, 67, 501-508. https://doi.org/10.1210/jcem-67-3-501
Krajewska, J., Jarzab, M., Czarniecka, A., et al. (2106) Ongoing Risk Stratification for Differentiated Thyroid Cancer (DTC)-Stimulated Serum Thyroglobulin (Tg) before Radioiodine (RAI) Ablation, the Most Potent Risk Factor of Cancer Recurrence in M0 Patients. Endokrynologia Polska, 67, 2-10. https://doi.org/10.5603/EP.2016.0001
Ceccarelli, C., Pacini, F., Lippi, F., et al. (1988) Thyroid Cancer in Children and Adolescents. Surgery, 104, 1143-1148.
Ozkan, E., Soydal, C., Araz, M., et al. (2017) May Preablative Thyroglobulin Level Be a Prognostic Indicator for Papillary Thyroid Cancer? Clinical and Medical Investigations, 2, 1-5. https://doi.org/10.15761/CMI.1000122
National Cancer Institute (2010) Surveillance, Epidemiology and End Results Program (SEER) Cancer Statistics Review, 1975-2007. National Cancer Institute, Besthesda.
Sisson, J., Giordano, T., Jamadar, D., et al. (1996) 131-I Treatment of Micronodular Pulmonary Metastasis from Papillary Thyroid Carcinoma. Cancer, 78, 2184-2192. https://doi.org/10.1002/(SICI)1097-0142(19961115)78:10 3.0.CO;2-U
Jukkola, A., Bloigu, R., Ebeling, T., et al. (2004) Prognostic Factors in Differentiated Thyroid Carcinomas and Their Implications for Current Staging Classifications. Endocrine-Related Cancer, 11, 571-579. https://doi.org/10.1677/erc.1.00826
D’Avanzo, A., Treseler, P., Ituarte, P.H.G., et al. (2004) Follicular Thyroid Carcinoma: Histology and Prognosis. Cancer, 100, 1123-1129. https://doi.org/10.1002/cncr.20081
Gulcelik, M.A., Gulcelik, N.E., Kuru, B., et al. (2007) Prognostic Factors Determining Survival in Differentiated Thyroid Cancer. Journal of Surgical Oncology, 96, 598-604. https://doi.org/10.1002/jso.20845
Lang, B.H., Wong, K.P., Cheung, C.Y., et al. (2013) Evaluating the Prognostic Factors Associated with Cancer-Specific Survival of Differentiated Thyroid Carcinoma Presenting with Distant Metastasis. Annals of Surgical Oncology, 20, 1329-1335. https://doi.org/10.1245/s10434-012-2711-x
Machens, A., Hinze, R., Thomusch, O., et al. (2001) Pattern of Nodal Metastasis for Primary and Reoperative Thyroid Cancer. World Journal of Surgery, 16, 22-28.
Lundgren, C.I., Hall, P., Dickman, P.W., et al. (2006) Clinically Significant Prognostic Factors for Differentiated Thyroid Carcinoma: A Population-Based, Nested Case-Control Study. Cancer, 106, 524-531. https://doi.org/10.1002/cncr.21653
Ronga, G., Filesi, M., Ventroni, G., et al. (1999) Value of the First Serum Thyroglobulin Level after Total Thyroidectomy for the Diagnosis of Metastasis from Differentiated Thyroid Carcinoma. European Journal of Nuclear Medicine, 26, 1448-1452. https://doi.org/10.1007/s002590050477
Webb, R.C., Howard, R.S., Stojadinovic, A., et al. (2012) The Utility of Serum Thyroglobulin Measurement at the Time of Remenant Ablation for Predicting Disease-Free Status in Patients with Differentiated Thyroid Cancer: A Mata-Analysis Involving 3947. The Journal of Clinical Endocrinology & Metabolism, 97, 2754-2763. https://doi.org/10.1210/jc.2012-1533
Hall, F.T., Beasly, N.J., Eski, S.J., et al. (2003) Predictive Value of Serum Thyroglobulin after Surgery for Thyroid Carcinoma. Laryngoscope, 113, 77-81. https://doi.org/10.1097/00005537-200301000-00014
Lin, J.D., Huang, M.J., Hsu, B.R., et al. (2002) Significance of Postoperative Serum Thyroglobulin Levels in Patients with Papillary and Follicular Thyroid Carcinomas. Journal of Surgical Oncology, 80, 45-51. https://doi.org/10.1002/jso.10089
Malandrino, P., Latina, A., Marescalco, S., et al. (2011) Risk-Adapted Management of Differentiated Thyroid Cancer Assessed by a Sensitive Measurement of Basal Serum Thyroglobulin. The Journal of Clinical Endocrinology & Metabolism, 96, 1703-1709. https://doi.org/10.1210/jc.2010-2695